Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Matrix Stiffening and EGFR Cooperate to Promote the Collective Invasion of Cancer Cells.
Grasset EM, Bertero T, Bozec A, Friard J, Bourget I, Pisano S, Lecacheur M, Maiel M, Bailleux C, Emelyanov A, Ilie M, Hofman P, Meneguzzi G, Duranton C, Bulavin DV, Gaggioli C. Grasset EM, et al. Among authors: bailleux c. Cancer Res. 2018 Sep 15;78(18):5229-5242. doi: 10.1158/0008-5472.CAN-18-0601. Epub 2018 Jul 19. Cancer Res. 2018. PMID: 30026329
CHEOPS trial: a GINECO group randomized phase II assessing addition of a non-steroidal aromatase inhibitor to oral vinorelbine in pre-treated metastatic breast cancer patients.
Bailleux C, Arnaud A, Frenel JS, Chabaud S, Bachelot T, You B, Stefani L, Tixidre CG, Simon H, Beal-Ardisson D, Jacquin JP, Del Piano F, Lortholary A, Cornea C, Greilsamer C, Largillier R, Brocard F, Legouffe E, Atlassi M, Hardy-Bessard AC, Heudel PE. Bailleux C, et al. Breast Cancer. 2023 Mar;30(2):315-328. doi: 10.1007/s12282-022-01426-1. Epub 2023 Jan 5. Breast Cancer. 2023. PMID: 36602669 Free PMC article. Clinical Trial.
Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program.
Bello Roufai D, Gonçalves A, De La Motte Rouge T, Akla S, Blonz C, Grenier J, Gligorov J, Saghatchian M, Bailleux C, Simon H, Desmoulins I, Tharin Z, Renaud E, Bertho M, Benderra MA, Delaloge S, Robert L, Cottu P, Pierga JY, Loirat D, Bertucci A, Renouf B, Bidard FC, Lerebours F. Bello Roufai D, et al. Among authors: bailleux c. Oncogene. 2023 Jun;42(23):1951-1956. doi: 10.1038/s41388-022-02585-3. Epub 2023 Jan 7. Oncogene. 2023. PMID: 36611120
Tucatinib Combination Treatment After Trastuzumab-Deruxtecan in Patients With ERBB2-Positive Metastatic Breast Cancer.
Frenel JS, Zeghondy J, Guérin-Charbonnel C, Mailliez A, Volant E, Poumeaud F, Patsouris A, Arnedos M, Bailleux C, Cabal J, Galland L, de Nonneville A, Guiu S, Dalenc F, Pistilli B, Bachelot T, Pierga JY, Le Du F, Bocquet F, Larrouquere L, Loirat D. Frenel JS, et al. Among authors: bailleux c. JAMA Netw Open. 2024 Apr 1;7(4):e244435. doi: 10.1001/jamanetworkopen.2024.4435. JAMA Netw Open. 2024. PMID: 38568692 Free PMC article.
Baseline metabolic tumor volume as a strong predictive and prognostic biomarker in patients with non-small cell lung cancer treated with PD1 inhibitors: a prospective study.
Chardin D, Paquet M, Schiappa R, Darcourt J, Bailleux C, Poudenx M, Sciazza A, Ilie M, Benzaquen J, Martin N, Otto J, Humbert O. Chardin D, et al. Among authors: bailleux c. J Immunother Cancer. 2020 Jul;8(2):e000645. doi: 10.1136/jitc-2020-000645. J Immunother Cancer. 2020. PMID: 32709713 Free PMC article.
36 results